Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of PN-235 in healthy volunteers
NCT04621630Phase 1Completed
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of icotrokinra in plaque psoriasis, ulcerative colitis (UC) and Crohn's disease (5 arms), sponsored by Protagonist Therapeutics, Inc. Primary endpoint: Safety of PN-235 at 10 days. Started Nov 2020; status: completed.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasisulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04621630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04621630.